Keywords: merck, co, hit, vioxx, withdrawal, sees, 4th-qtr

Merck & Co, hit by Vioxx withdrawal, sees 4th-qtr EPS in line with expectations

Article | 31 January 2005

Print This

Troubled US drug major Merck & Co, which last September withdrew its blockbuster COX-2 inhibitor arthritis drug Vioxx (rofecoxib) on safety ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in